Navigation Links
Start Licensing, Inc. Welcomes FDA's Finding of Safety of Food From Cloned Animals
Date:1/16/2008

AUSTIN, Texas, Jan. 16 /PRNewswire-USNewswire/ -- Start Licensing, Inc. ("Start"), a joint venture of Geron Corporation (Nasdaq:) and Exeter Life Sciences supports the final risk assessment released by the US Food and Drug Administration on January 15. The assessment concluded that meat and dairy products from animal clones and their offspring are safe for human consumption.

"FDA's conclusion is consistent with a report released January 11, 2008 by the European Food Safety Authority and studies in other countries. These findings open the door to widespread adoption of the technology platform to enhance the quality of meat and dairy products" said Jonathan Thatcher, president of Start. "With this safety conclusion, ranchers and livestock producers can look to cloning technology to rapidly increase the best genetics, including quality and health traits, in their herds."

Created in 2005, Start is a joint venture of Geron Corporation (Nasdaq: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a worldwide portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute. The nuclear transfer patents managed by Start have been upheld by the US PTO in three separate patent interference proceedings and in opposition proceedings by patent offices in other countries. Start's licensees are engaged in research and product development in food production, medical applications and other fields.

For more information call Natalie Garrett, Start Licensing/Turner Strategies, 202-466-9633


'/>"/>
SOURCE Start Licensing, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC
2. Visiprise Manufacturing Wins START-IT Top 50 Technologies Award
3. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
4. Optherion, Inc. Completes $37 Million Start Up Financing
5. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
8. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
9. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
10. Industry Executives Finding Value in Shift of Scientific Publications
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental challenge ... to full-size tissues, bones, even whole organs to implant in people to treat ... deep into the developing tissue. , Current bioengineering techniques, including 3-D printing, ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
Breaking Biology Technology:
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
Breaking Biology News(10 mins):